Form 4: Kymera Director Sells Shares Under Pre-Arranged Plan

Kymera Therapeutics Director Elena Ridloff executed planned sales of common stock totaling 12,000 shares in late March and early April 2026, following option exercises.

Summary

• Elena Ridloff, a Director at Kymera Therapeutics, Inc. (KYMR), reported transactions involving the company's common stock.
• On March 31, 2026, Ridloff exercised options to acquire 7,400 shares of common stock at an exercise price of $14.18 per share.
• Immediately following the option exercise on March 31, 2026, Ridloff sold all 7,400 shares at a weighted average price of $85.3701 per share, with individual sales ranging from $85.04 to $85.64.
• On April 1, 2026, Ridloff exercised options to acquire 4,600 shares of common stock at an exercise price of $14.18 per share.
• Also on April 1, 2026, Ridloff sold 3,400 shares at a weighted average price of $85.1946 per share (ranging from $85.00 to $85.97) and an additional 1,200 shares at $86.05 per share.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan established on December 11, 2025.
• The stock options exercised were fully vested and exercisable, with an expiration date of June 15, 2032.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reports routine insider transactions executed under a pre-arranged 10b5-1 plan, which is a common practice for personal financial management and does not inherently signal a change in the company's operational outlook or performance.

Positives

• The exercise of stock options at $14.18 and subsequent sale at prices above $85 indicates a significant increase in the company's stock value since the options were granted, reflecting positive past performance.
• The transactions were executed under a Rule 10b5-1 trading plan, demonstrating pre-planned and transparent insider trading practices.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by investors as a lack of conviction in the company's future growth, although this is mitigated by the 10b5-1 plan.

Risks

• While executed under a 10b5-1 plan, any significant volume of insider selling could lead to negative market sentiment or speculation, potentially impacting the stock price.
• The reporting person no longer holds any derivative securities (stock options) following these transactions, reducing their direct equity incentive tied to future stock price appreciation from these specific options.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider sales executed under Rule 10b5-1 trading plans are a common practice for corporate executives and directors. These plans allow insiders to pre-arrange sales of company stock at a future date, providing an affirmative defense against claims of insider trading by demonstrating that the trades were not based on material non-public information. Such transactions are typically for personal financial planning, diversification, or liquidity purposes and are generally viewed as routine within the industry.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices for corporate governance and transparency in insider trading, consistent with standards observed across publicly traded companies in the biotechnology and pharmaceutical sectors.
• While the specific transaction values are unique to Kymera Therapeutics and the individual director, the mechanism of exercising vested options and selling shares is a standard compensation and liquidity event for executives and directors across industries, including peers like Moderna (MRNA) or BioNTech (BNTX) where similar insider transactions occur.

Stakeholder Impact

• Shareholders: May interpret the insider selling with caution, though the 10b5-1 plan mitigates concerns about trading on non-public information. The significant profit from option exercise could be seen positively as a reward for past performance.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Form 4, insider trading, stock option exercise, share sale, 10b5-1 plan, director transaction, beneficial ownership